By Dhirendra Tripathi
Investing.com – Johnson & Johnson (NYSE:JNJ) stock was trading higher during Friday’s premarket trading as findings from a small lab study indicated that the company’s single dose COVID-19 vaccine may be effective against the Delta variant of the coronavirus.
In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday. The company released the high-level findings through a press release, not a detailed peer-reviewed study.
After the virus originated in China in 2019 and spread to other countries, it has mutated several times. Delta is a variant that first emerged late last year or early 2021 in India and is now the most prevalent and also the deadliest virus in most countries.
Vaccines that show a high degree of effectiveness against mutations of the virus – of which many will surely follow – have a batter chance of gaining market share as the world prepares for a long campaign against Covid-19.
J&J Gains As Vaccine Shows Promise Against Delta Variant
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.